Research Topic: existential distress

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey

mycolabadmin

This study surveyed 2,800 Canadians about their views on using psilocybin (a psychedelic compound from certain mushrooms) to help patients with terminal illnesses manage existential distress and anxiety. About 79% of respondents thought it was a reasonable medical option, and 85% believed the government should cover the costs. People who had previous experience with psilocybin, those exposed to palliative care, and those with progressive political views were most supportive of this therapy.

Read More »

Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences

mycolabadmin

People who use psychedelic substances like psilocybin or LSD sometimes experience profound changes in how they understand reality that can be distressing and last for months or years. This study interviewed 26 people who went through such difficult experiences and found that what helped them most was practicing grounding techniques (like yoga, spending time in nature, and creative activities), talking about their experiences with others, and learning to accept their new perspectives. The research shows that while these experiences can be challenging, people can recover and grow from them with the right support and practices.

Read More »

Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress

mycolabadmin

A study asked 31 palliative care patients about their views on using psilocybin (a compound from magic mushrooms) as a treatment for existential distress—the emotional and spiritual suffering that comes with terminal illness. Over half the patients were interested in trying this therapy, especially if they believed it could help with anxiety and stress. However, patients were concerned about risks like psychosis, the lack of trained therapists, and the potential for doctors to take advantage of them during treatment. The researchers concluded that while psilocybin-assisted therapy shows promise, there needs to be better education and strict safeguards to protect vulnerable patients.

Read More »

Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report

mycolabadmin

A 54-year-old man with terminal throat cancer received a single dose of LSD (100 μg) as part of psychedelic-assisted therapy delivered at his home. The treatment helped him experience relief from existential distress and feelings of peace. Six months later, he was in better psychological health, more motivated to pursue meaningful activities, and had discontinued pain medications while maintaining stability. This case demonstrates that psychedelic therapy can be safely administered at home for patients with life-threatening illnesses seeking existential relief.

Read More »
Scroll to Top